UNSPSC 51434808: Iprotiazem

This classification denotes a calcium channel blocker with the molecular formula C37H49N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VPX99Q2D7, chemically known as ( )-(r)-2-isopropyl-4-methyl-2-(o-(4-(4-(3,4,5-trimethoxyphenethyl)-1-piperazinyl)butoxy)phenyl)-2h-1,4-benzothiazin-3(4h)-one. but generally known as iprotiazem, which bears US NIH Compound Identifier 195131. European Medicines Agency schedules Iprotiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08286MIG.

UNSPSC 51434808 Iprotiazem is a Commodity code under which state and local governments procure specific pharmaceutical products for emergency medical services, public health programs, and cooperative purchasing agreements serving multiple jurisdictions. Recent solicitations show state and local buyers purchasing both individual active pharmaceutical ingredients and formulated medications—from advanced life support drugs for fire rescue services to generic multi-source pharmaceuticals distributed through statewide cooperative purchasing alliances. The work encompasses product specification, sourcing, warehousing, and delivery compliance, with vendors required to meet FDA standards, expiration-date guarantees, safety documentation (OSHA Safety Data Sheets), and accessibility requirements. Issuing bodies include city purchasing departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing organizations serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity concentrates in the Southeast and Midwest, with solicitations posted from Tampa, Florida; Texas; Minnesota; and Oregon. The City of Tampa issued an IFB (Bid No. 26P00188) for Advanced Life Support Medications with a response deadline of April 8, 2026, requiring four specific formulated products (Labetalol, Epinephrine, Adenosine, Diltiazem) totaling an estimated $40,000, with a Small Local Business Enterprise 5 percent bid discount available. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesaler channels. MMCAP issued a multi-state RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with pricing weighted at 75 percent and contract terms effective July 1, 2026. Vendors must maintain insurance coverage (commercial general liability $5 million per occurrence), comply with cGMP and Drug Supply Chain Security Act requirements, and accept a 3 percent administrative fee on all purchases.